- NewsCategory：
- All Company news Industry news
common83One result
-
0927
NeuCyte Licenses Promisi♣§✘ng Novel Compound for Treatme€↑Ωnt of Refractory Epilepsy and Relate✘≥d Neurological Disorders
NeuCyte, Inc., an innovative biotech company ♣✔×focused on developing novel treatments for®¥£ neurological disorders, today→± announced that it has entered into an exclus©σ♣ive license agreement with Trillium Therap∑•eutics to advance an undisclos♠∏ed preclinical compound with potent€©ε§ial utility in treating refractory ep™→₽ilepsy in the form of Dravet syndrome and relatedα₹→ disorders.The compound covered by this agr&λ✘eement has demonstrated highly encouraging ×€activity during studies conducted by the Nationaδ ←l Institute of Neurological Disorders and Str•♠ oke (NINDS) Epilepsy∏§ Therapy Screening Pβ&↔σrogram (ETSP). It demonstrates↕♠ a superior safety and anti-seiz&§↕αure efficacy profile over NINDS benchmarεφ₹σk anti-epileptic drugs (AEDs)&∞≠₽ in eleven animal models. It has also demo←≈nstrated broad efficacy in NIH animal studies foδ>' r pharmaco-resistant epilepsy. As a r∏α'esult, this novel agent has gλφ£≈ained the prestigious NINDS§≠γ Red Book status and been selected as a pro≤λmising lead drug can¥☆didate."This compound is an e¥★Ωxceedingly promising ant↑↑÷iseizure drug which, al ↔though in preclinical development, is quit¶ e efficacious in a wide variety of highly☆≈ predictive seizure models," said Roger< ' J. Porter, MD, Adjunct Professor of ↓ Neurology at the Univer₩∞♥sity of Pennsylvania, former Deputy Director o↕♥Ω→f NINDS, former Chairm ≈an of the White House C≈↑λommittee on Brain and Behavioral&π Sciences, and former President of American Ep✘↑'φilepsy Society. "It may÷™ prove very effective for patients wi <th epilepsy." As a first-in-&¶class compound with un∑±πβique mechanism of action profiles, this drug cand<↔idate is likely to have activity♠↔ across a variety of indications. The®♥$→ favorable efficacy andπ∑© safety profile has also been validated by NeuC≠¥≈yte's proprietary in vitro human☆☆ iPSC-derived models."Epileps'★©y is the fourth most common neurological d↔Ωisease affecting more than☆α 65 million people of all ages worl♥₩<dwide. The complex and multifε✔βactorial nature of the disorders makes treaσ∞tment complicated and challenσ✘γ↓ging. Up to 40% of newly diagn★₩≤₹osed epilepsy patients are resistant to ♠¥★current therapies whδ∞ich highlights the ur&<←gent need to develop first-in∑¥®-class treatments," said Jacqueline A. French, M≥¥♣₩D, Chief Medical and Innovat>§ion Officer of the Epilepsy∑✔↓ Foundation and epileptologist in New Yσ≥ork City. "It is very encouraging to see new&"♦ developments and therapeutic c✔™¥σandidates in this disea∑÷se area."Under the term♦♠s of the agreement, Trillium has grant©→$↑ed NeuCyte exclusive, worldwide rights to develo₹♠p and commercialize the comp<≥€♠ound. "NeuCyte is committed to bringing'∏∏ breakthrough therapies to epile↕€psy patients and believ•≤e that our advantageous translational tech∏ ♣☆nology platform and CNS expertise↑₩↔≈ enable us to optimally a®'dvance such therapeu↑→∏•tic candidates," said Tao Huang, ε₩ PhD, JD, President and Chieλ↕f Executive Officer of NeuCyte. "This licensi₽≥ng agreement allows us to expand our pipeline €£&and advance our goal of meeting ±•☆☆unmet clinical needs and truly improving patie >σnt care and quality of life."∑♠∑information source:pharma f& ocus AsiaThe original link:https:htt≈Ωps:https://www.pharmafocusasia.com/news/nδ≤ eucyte-licenses-promising-novel-compoun∏↑ βd-for-treatment-of-refractory-epilepsy-and₽-related-neurological-disorders2019 Asia-pacif"™♣¥ic pharma IP Leader Summi≠♥÷t:http://en.zenseegroup.c•÷om/p/510934/will be held in∑×® Beijing on Novem™&ber 14-15, and will attract moreδ< than 500 industry experts froπ•m domestic and foreign pharmaceutical companε©£ies, biotechnology companies, governments, ass→↕ociations, law firms, intellectual p×£₽¶roperty agents and other companies to attend.Offi•π$cial registration and consultation chan↑"γσnels:Contact：AnnPhone: 021-65650305Email：Marketing@zenseegrou£∏p.comhttp://en.zenseegroup.com/p/510934/ -
0926
Ivy Brain Tumor Cent"≈♠φer and BridgeBio Subsidiary QED Thera♠εpeutics Announce Collaboration₩Ω→₹ to Advance Cancer Research and Tre≈§atment Options
The Ivy Brain Tumor Center at Barrow Nλ±eurological Institute, today ann₹×ounced a new collabora≥÷φ¥tion with QED Therapeutics, Inc., σβ♣>a subsidiary of BridgeBio Pharma, Inc., (Na"$✔sdaq:BBIO) to investigate the FG☆φ≤FR1-3 tyrosine kinase inhibitor©£↑, infigratinib, for the trea≥σtment of glioblastoma (GBMΩ♦π₩). With the goal of addressing™↑α unmet medical needs for those© Ω affected by malignant brain cancer, this collabo®≥←ration will focus on targeting FGFR (fibrobla §st growth factor receptor) genetic alterations ♦Ω÷δthat have been shown to sφ♦pur growth in malignant tumors.“Five to seven p×☆ercent of glioblastoma patien₽§¶ts’ tumors are driven by FGFR signaling,” saiΩ≤↓d Dr. Nader Sanai, director of the Ivy Bra♦ £in Tumor Center. “We believe our colla↔÷σ≤boration with QED Therapeuti♠¶cs will enable us to test how FG ★FR-driven GBM tumors respond to infigratinib. I f proven effective, we then intend to mov ®©e forward new combined drug s✘÷ trategies incorporating this target.”In t ☆≠αhe preclinical studies, the Iλ×≈vy Center will employ orthotopi® cally implanted, wel ←←l-characterized FGFR3 fusion patient-derivδδ≤♠ed xenograft models. ↑¥&This is intended to allow the team to further e"≠xplore the extent to wh≈ε≥∏ich the drug crosses the blood-brainγβ barrier and what activity it ™☆has in the brain.“We bΩ÷elieve the work we a×₽re undertaking with the Ivy Center wφβ±×ill provide critical insight to shape©↑ our clinical develop♠₽ment strategy for thi ₽s disease,“ said Sus•↓an Moran, M.D., M.S.C.E., chief medical officer∞÷β of QED Therapeutics. “Our hope is tha∏÷t infigratinib will b© ✔ecome the backbone of new combination therφ§<apies to treat patients wΩ<♠ith glioblastoma.”Infigratinib is an orally adφministered, FGFR1-3 selective tyrosin₽ e kinase inhibitor. QED Therapeutics has obser•♣γved activity that appears to be meaningful in cl≈¶inical trials for caΩ••ncers that are driven by err∏γ✘ors in the FGFR genes. T₩β≤hese include chemotherapy-refractor₹£✘y cholangiocarcinomaφ€ with FGFR2 fusions and↓✔∞ advanced urothelial carcα¥Ω÷inoma with FGFR3 genet"∞☆&ic alterations.“The intricaci©×£es of the brain have posed significa±✘∑nt challenges for brain cancer research an♦d the development of therapies,” Ω'said Gary Li, head of translational medicineα ↕ at QED Therapeutics. “We believe collabor✔"ating with the Ivy Brain Tumor C€σenter will enable us to move swα∑δ✔iftly and further translational research &±↔→that we hope will unlock 'Ω&the doors to effective♥β treatment options.”inf✔α€↕ormation source:pharma focus Asiβ aThe original link:https:https://www.pharmafocu₹✘ sasia.com/news/ivy-brain-tumor-center-and-bridgeb☆↕io-subsidiary-qed-therapeutics-anno>unce-collaboration-to-advance-cancer-research-and>€-treatment-options2019 Asia-p©¶∏acific pharma IP Leader Summit:http:/✔•₩ /en.zenseegroup.com/p/510934/wil♠₹l be held in Beijing on&∑®φ✔nbsp;November 14-15, and will attract ≥<←δmore than 500 industry experts from domestic ¥↕∞and foreign pharmaceutical companies, bi★σ↓otechnology companies, governments, associa¶₹λ♠tions, law firms, intellectual property aφ∏gents and other companies to attend.Offi∏×☆cial registration and consultationβ↑ channels:Contact：AnnPhone: 021-65650♥>γ"305Email：Marketing@zenseegroup.comhε∞≠±ttp://www.zenseegrouφ♣÷'p.com/forms/view/22113/ -
0925
I-Mab Biopharma Announces'" Clinical Collaboration to Evaluate TJC4 in C ↑ombination with KEYTRUDA®•∞< (pembrolizumab)
I-Mab Biopharma ("I-Mab")>✘•, a China and U.S.-based clinica> l stage biopharmaceutical comp₩→♥any exclusively focu"•£sing on the discovery and devel★♥✘♦opment of potential first-in∏←-class and best-in-class biol&↔'εogics in immuno-oncologλ☆y and autoimmune diseases, today announced th♦Ωat it has entered into a clinical researc↔→h collaboration agreement with MSD, a t∑™radename of Merck & Co., Iφπnc., Kenilworth, NJ., USA, to ✘✔evaluate the combination±★× of I-Mab's TJC4 and MSD's anti-PD-1≥ ✘€ therapy, KEYTRUDA® (pembrol≤izumab) in patients with multiple cancer types.U←nder this collaboration agree∏±>•ment, MSD will supply KEYTRUDA® (peσ≈mbrolizumab) to I-Mab for use in clinical s✘"α↑tudies in combination with TJC4, a fγ♠'ully human anti-CD47 monoclonal an φtibody. Both parties wi∏φll collaborate on a Phase ∞∑1 clinical trial, based o"₩βn an agreed and finalized protocol, to evaluate★ the safety, pharmacokinetics, pharmacod±₩ynamics and preliminary e↑₽®♦fficacy of TJC4 and KEYTRUDA® in patients wit←®•h multiple cancer types."TJC4 is a highly di₽ fferentiated anti-CD47 antibody ↕€currently under clinical deve®∏¶ lopment. This collaboration wi<σλll provide an excellent ×☆€♠opportunity to further explore t©αherapeutic potential of c≠✔∏ombining TJC4 with KEYTRUDA® ac♥↔φross different tumor types." sai©'€d Dr. Jingwu Zang, Founder and Chairman ✘of I-Mab.KEYTRUDA® is a registered trad¥λemark of Merck Sharp & Do&✘hme Corp., a subsidiary of Merck &&•∏amp; Co., Inc., Kenilworth, NJ, USA.inf↑ormation source:pharma focus AsiaTheσφ∑ original link:https://www.pha₹α↕₹rmafocusasia.com/news/i-mab-biopharma✔• -announces-clinical-collaborationφπ§-to-evaluate-tjc4-in-combination-with-keytrud≈&'a2019 Asia-pacific pharma IP L Ω÷♣eader Summit:http://e£↕n.zenseegroup.com/p/5γ♦π♠10934/ will be held in&n≈★bsp;Beijing on&nσ♣™bsp;November 14-15, and wil≠≈l attract more than 500 industry experts from€φ≠& domestic and foreign phΩ armaceutical companies, biotechn∏≤≠ology companies, governm↑Ω♦ents, associations, law fi♦©rms, intellectual property agents and other &β companies to attend.Official registratio∞≈αn and consultation channels:Contact：AnnPho ♦↓λne: 021-65650305Email：Marketing@ze©₩nseegroup.comhttp://www.zenseegroup.com¥σ≠→/forms/view/22113/ -
0923
Boehringer Ingelheim Partners €δ↔"with Inflammasome Therap§<γ♠eutics to Develop Novλ₩el Therapies for Patients with Retinal D✔€₽iseases
Boehringer Ingelheim and α¶>↓Inflammasome Therapeutics Inc. (I←nflammasome) today ann§♥ounced they have entered into a ∏☆co-development and license agreemen€"£×t to develop up to three therapies for∞₽λ patients with retinal diseases. By ✔$combining Inflammasome’s unique intr>≈<avitreal (IVT) drug delivery techn★±÷ologies with Boehringer Ingelheim’s compounds✔σ♥≠ from its retinal disease pipeline portfolioφ≥α™, Boehringer Ingelheim aims to devel≥§op novel therapies for ×₹retinal diseases.In 2019 there were an es₩σ±♦timated 82 million patie✘&nts in the seven key countries (↑✘→U.S., Japan, Germany, U.K., Spain, Italy, Fraγ±nce) affected by one of the ←$€three major forms of retinal disease: ✘π♣Age related macular degeneration (AMD), diabet×÷"ic retinopathy (DR), and diabetic macular ₹>₩♦edema (DME). Globally, the pr"σ®evalence rates of these and other ↑↕§retinal diseases are expected ¶♣©to increase over the next 10 years prim &arily due to aging popu™&→lations and the global diabetes epidemic. Despite∏§β÷ therapeutic advances in some disease areas duri×♥αng the past years, the real world re ¥☆sults are poor, and there aγre no or only limite$©↔d treatment options in many a₹✔♣∏reas, resulting in an§$ overall high unmet need. The collaboration bet☆ •ween Boehringer Inge•lheim and Inflammasome aims to addreφ✔ss this challenge by u Ω∏sing Inflammasome’s tec≠÷÷hnology to deliver thera♣∏peutics in a biodegr≤adable gel formulation&γ into the eye.“We are delig∑&hted to enter into a collaboration with aσ® company of Boehringer ♣$&Ingelheim’s stature,” said Paul Ashton, Chδ→<↓ief Executive Officer of Inflamm×'asome Therapeutics. “∞¶We look forward to worki✔δng with their team to leverage our respective™♣ technologies and expertise to develop new t∏₩≥↓herapies for devastating retin↔¶↑al diseases leading to blindness. Thi₹εs collaboration fits our strategy of ad£∏vancing the company via both collaboratio♥≤♠¶ns and internal development.”“Boehringer Ingelhei© β®m is looking forward to devλ★>>eloping Inflammasome’s novel technologε↔y for the delivery of o✔±♦ur first-in- class retinal disease compounds w α≠orking jointly with Inflammasome’s¶φ highly experienced scientific team,” s∑♦aid Clive R. Wood, PhD, Sen♣"ior Corporate Vice President, D≠≠β→iscovery Research at Boehringer π>Ingelheim. “This will enable us to devel↓≤•op a broad range of noφ<&↑vel therapy options for the many patients →'Ωwith retinal diseases waiting u∑λ₽rgently for better and new therapy options.”Boehrσ<inger Ingelheim takes a holistic≥∏ approach in the development↕£ of novel retinal disease therapie≥™s, targeting key mech'±'anisms in the pathogenesis of retinal diseases. ↑ ΩThe company has built a comprehe <↔<nsive pipeline portfolio of next gener™σ≠✔ation therapy approaches in various stag±γes of development up to Phase 2™§ in macular degeneration, diabetic retinal d¥iseases and beyond. In♦★≤₩flammasome’s novel delivery tec∞✘hnology using a long-acting degradable ∑↔IVT implant complements this portfolio.In§α↓•flammasome is entitled to receive up to $160™↑ million in up-front'α←, research and development support an↔∏$↑d milestone gated development payments as w₽©εell as tiered royalties↓©≠σ based on future commercial sale£↔←s of developed products and other milestones due on commercialization.information&nb$₩sp;source:pharma focus AsiaThe original linkΩ:https://www.pharmafoc∑♦£usasia.com/news/boehri≥∞₩nger-ingelheim-partners-with-inflammasom≠∞α e-therapeutics-to-develo¥♠♥£p-novel-therapies-for-patients-with>ε-retinal-diseases2019 Asia-pacific <pharma IP Leader Summit: http://en.zenseeg÷∑roup.com/p/510934/will be held in Beφ"$£ijing on "ε;November 14-15, and will attract more₩α← than 500 industry experts€≤¥ from domestic and fore'αign pharmaceutical companies,÷ biotechnology companies, g↑₽overnments, associations, lΩπ¥®aw firms, intellectual propertyπ↔$γ agents and other companies to attend.Of₹σ↕ficial registration and consultation channel±δ™s:Contact：AnnPhone: 021-65650305Eφ§γ&mail：Marketing@zenseegroup.comhttp://www.zensee>λ™•group.com/forms/view/22113/ -
0920
Clene Nanomedicine, Inc. Announces Selection∞♣∞∞ of CNM-Au8 for the Harvard Led H€&φ☆EALEY ALS Platform Trial, a Clinical Tr₽↓ ial for Amyotrophic Lateral Sclerosis
Clene Nanomedicine, Inc¶♣ ., a clinical-stage biopharmace'✘→utical company, announced today tha≈§★t the Sean M. Healey & AMG Center for ALS at♥"÷ Mass General has selected CNM-Au8 fo♥≤r inclusion in the first' £↑ ever Platform Trial fo≤ <↕r the treatment of amyotrophic lateral sclero•∏÷sis (ALS).The Healey Center issued a ca•γ≈αll earlier this year↔±∏γ for the best therapeutic candidaו×tes to apply for entryσ≥ into the HEALEY ALS Platform Trial. They receive↔♦♠d responses from nearly 30 applicants across t<¥en countries. Members from the Healey Center Sγ☆ πcience Advisory Committee, a group of renow "∑ned ALS scientists, chose the top five t≥ herapeutic candidates∑≤₩, including Clene's lead clinical as↓®σset, CNM-Au8. The selection of CNM-Au8 into≈δ the Healey ALS Platfor↑©αm Trial includes substantial financial suppor→ ₹↔t and provides access to over 50 expert ALS clinical trial sites across the UnΩ≠♣ited States."Our goal," said →λ ∏Merit Cudkowicz, MD, M₹&β™Sc, Director of the Healey Center¶"©φ, "is to lower the barriers fo>€r our pharma and academ™₹'₽ic colleagues to bring their☆∑ exciting therapies for ALS forward σ↑&to clinical trials. We are de↓πtermined to accelerate therapy development fo♣✔r ALS."Important preclinicalλβ work supporting the↑ effort with CNM-Au8 was performed in the laborat✘↓φory of Nicholas J. Maragakis, Direc∞£©tor of the ALS Center fo♥®≤r Cell Therapy and Re¥"↔ generation Research at Johns Hopkiλσ≈λns, using human induced plurip★₽otent stem cells from ALS patients. Dr. MaragakΩ&is is Chair of Clene's ↓ε♦Scientific Advisory Board fπβor ALS.Dr. Jonathan Glass, Professor of Neurol∞γogy and Pathology at Emory University School of ©♥♦≠Medicine, as well as Director of the Emory ALSφ€ Center, remarked, "CNM-Au8 is quite an i"'nteresting compound that ↔δ≤is ready for testing in ALS clinical trials.&nb↕sp; Its inclusion in the Platform Trial &÷♦©initiative is an excellent way to moveεδ£ forward for the developme♣ nt of CNM-Au8 as a potential t>σherapeutic for ALS.""We are v↔ ery pleased Clene's CNM-Au8 has '"been selected for partic>σσ♦ipation in the Healey ALS Platform Trial. W&≠e believe the unique mechanism oγβf CNM-Au8 represents a α♥promising new approach for the ≥★₩✔treatment of neurodegenerativ ♦πe diseases, including ALS, with the p★>÷otential for meaningful impact for the c♠∞ ≥ommunity of people diagnosed with this ✔βdevastating and debilitating disease," said Rob→☆ Etherington, Presidentα™↕¥ and CEO of Clene. "We are continuing ↑♠the development of CNM-Au8 in sever≥ al clinical studies set to launch later this y ↕ear."2019 Asia-pacific pharπ£¶ma IP Leader Summit: http://en.zenseegroup"$<↕.com/p/510934/will be held in Beijing γ€ on November 14-15, and will attract✘ α more than 500 industry experts from domestic©♦< and foreign pharmaceutical companies¥<, biotechnology companies, governments, associatiβ₹£≠ons, law firms, intellectual ≥₩σproperty agents and other co♦♣mpanies to attend.Official registration and consu✘ ltation channels:Contact：AnnPhon&πe: 021-65650305Email：Marketing@zenseegroup.comhtt₽λα₹p:/Ωβforms/view/22113/
Contact Us
Zensee_Daystar online
© 2011-2016